Can we still consider thyroid hyperfunction a protective condition for the onset of thyroid cancer?

Thyroid hyperthyroidism microcarcinoma occult carcinoma thyroid cancer

Journal

Gland surgery
ISSN: 2227-684X
Titre abrégé: Gland Surg
Pays: China (Republic : 1949- )
ID NLM: 101606638

Informations de publication

Date de publication:
Apr 2021
Historique:
entrez: 10 5 2021
pubmed: 11 5 2021
medline: 11 5 2021
Statut: ppublish

Résumé

Thyroid cancer is the ninth most commonly diagnosed cancer in the world, and the most common endocrine carcinoma. It was originally believed to be a rare event in patients with thyroid hyperfunction and it was reported that hyperthyroidism had a protective role against thyroid neoplasms. However, in recent years, several studies have hypothesized that differentiated thyroid carcinomas and hyperthyroidism may coexist. Our study aims therefore to evaluate the incidence of differentiated thyroid carcinomas on definitive histological examination, in patients undergoing total thyroidectomy or hemithyroidectomy with coexisting hyperfunctioning thyroid disease, to understand whether hyperthyroidism can be considered a protective condition against the onset of thyroid neoplasms. The study involved 1,449 patients underwent to thyroid surgery from 2010 to 2018 at the General Surgery Unit, Department of Surgery, University Hospital of Parma, Parma, Italy, presenting thyroid cancer at postoperative histological exam. Patients were divided in two groups based on the presence (Group A) or absence (Group B) of hyperfunction. All data were collected in a dedicated database and include demographic data, such as age and sex, preoperative cytology, date and type of surgery, postoperative diagnosis, characteristics of aggressiveness of the neoplasm and postoperative complications. For data analysis, a P value of less than 0.05 was considered statistically significant. The incidence of thyroid carcinomas was lower in patients suffering from hyperfunction compared to the incidence found in non-hyperthyroid patients, both in preoperative cytological examination and in postoperative diagnosis through histological examination. Furthermore, the tumors that have developed in patients with hyperfunction had a comparable degree of aggression and invasiveness in the two groups studied. However, we have found an equal incidence of microcarcinomas and occult carcinomas on postoperative histological examination. Postoperative complications in patients with cancer were similar, regardless of the presence or absence of hyperfunctioning thyroid disease. Our study confirms that hyperthyroidism is a protective condition against thyroid carcinoma, but the finding of an equivalent incidence of occult carcinomas in the two groups stresses the need to perform a cytological examination in case of a nodular pathology in a hyperthyroid patient before performing a treatment.

Sections du résumé

BACKGROUND BACKGROUND
Thyroid cancer is the ninth most commonly diagnosed cancer in the world, and the most common endocrine carcinoma. It was originally believed to be a rare event in patients with thyroid hyperfunction and it was reported that hyperthyroidism had a protective role against thyroid neoplasms. However, in recent years, several studies have hypothesized that differentiated thyroid carcinomas and hyperthyroidism may coexist. Our study aims therefore to evaluate the incidence of differentiated thyroid carcinomas on definitive histological examination, in patients undergoing total thyroidectomy or hemithyroidectomy with coexisting hyperfunctioning thyroid disease, to understand whether hyperthyroidism can be considered a protective condition against the onset of thyroid neoplasms.
METHODS METHODS
The study involved 1,449 patients underwent to thyroid surgery from 2010 to 2018 at the General Surgery Unit, Department of Surgery, University Hospital of Parma, Parma, Italy, presenting thyroid cancer at postoperative histological exam. Patients were divided in two groups based on the presence (Group A) or absence (Group B) of hyperfunction. All data were collected in a dedicated database and include demographic data, such as age and sex, preoperative cytology, date and type of surgery, postoperative diagnosis, characteristics of aggressiveness of the neoplasm and postoperative complications. For data analysis, a P value of less than 0.05 was considered statistically significant.
RESULTS RESULTS
The incidence of thyroid carcinomas was lower in patients suffering from hyperfunction compared to the incidence found in non-hyperthyroid patients, both in preoperative cytological examination and in postoperative diagnosis through histological examination. Furthermore, the tumors that have developed in patients with hyperfunction had a comparable degree of aggression and invasiveness in the two groups studied. However, we have found an equal incidence of microcarcinomas and occult carcinomas on postoperative histological examination. Postoperative complications in patients with cancer were similar, regardless of the presence or absence of hyperfunctioning thyroid disease.
CONCLUSIONS CONCLUSIONS
Our study confirms that hyperthyroidism is a protective condition against thyroid carcinoma, but the finding of an equivalent incidence of occult carcinomas in the two groups stresses the need to perform a cytological examination in case of a nodular pathology in a hyperthyroid patient before performing a treatment.

Identifiants

pubmed: 33968687
doi: 10.21037/gs-20-688
pii: gs-10-04-1359
pmc: PMC8102229
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1359-1367

Informations de copyright

2021 Gland Surgery. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/gs-20-688). The authors have no conflicts of interest to declare.

Références

J Surg Res. 2011 Sep;170(1):96-9
pubmed: 21550063
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2015 Aug;37(4):402-5
pubmed: 26564455
Br J Surg. 2014 Mar;101(4):307-20
pubmed: 24402815
Int J Surg. 2016 Mar;27:118-125
pubmed: 26626367
Surgery. 1985 Dec;98(6):1148-53
pubmed: 2866590
Minerva Endocrinol. 2009 Dec;34(4):281-8
pubmed: 20046157
Langenbecks Arch Surg. 2012 Oct;397(7):1133-7
pubmed: 22976368
Eur Rev Med Pharmacol Sci. 1999 Nov-Dec;3(6):265-8
pubmed: 11261738
N Engl J Med. 1988 Mar 24;318(12):753-9
pubmed: 3347223
Am J Otolaryngol. 2020 Mar - Apr;41(2):102187
pubmed: 31757411
Chirurgie. 1998 Dec;123(6):604-8
pubmed: 9922602
Kaohsiung J Med Sci. 2003 Aug;19(8):379-84
pubmed: 12962424
Eur J Intern Med. 2003 Aug;14(5):321-325
pubmed: 13678758
J Clin Endocrinol Metab. 1992 Sep;75(3):886-9
pubmed: 1517381
Surgery. 2019 Sep;166(3):356-361
pubmed: 31104806
World J Surg. 1990 May-Jun;14(3):437-40; discussion 440-1
pubmed: 2368449
Thyroid. 2017 Jun;27(6):825-831
pubmed: 28457178
Am J Otolaryngol. 2014 Nov-Dec;35(6):784-90
pubmed: 25128909
Postgrad Med J. 1999 Mar;75(881):169-70
pubmed: 10448499
Eur J Endocrinol. 2008 Dec;159(6):799-803
pubmed: 18819945
J Clin Endocrinol Metab. 1990 Apr;70(4):826-9
pubmed: 2180977
Thyroid. 2017 Nov;27(11):1341-1346
pubmed: 29091573
Horm Res. 2003;60(2):79-83
pubmed: 12876418
G Chir. 2019 May-Jun;40(3):174-181
pubmed: 31484005
Drug Saf. 2000 Feb;22(2):89-95
pubmed: 10672891
Eur J Endocrinol. 2017 May;176(5):591-602
pubmed: 28179452
J Otolaryngol Head Neck Surg. 2018 Jan 22;47(1):6
pubmed: 29357932
J Surg Res. 2020 Jan;245:523-528
pubmed: 31450040

Auteurs

Elena Bonati (E)

General Surgery Unit, Department of Medicine and Surgery, Parma University Hospital, Parma, Italy.

Stefania Bettoni (S)

General Surgery Unit, Department of Medicine and Surgery, Parma University Hospital, Parma, Italy.

Tommaso Loderer (T)

General Surgery Unit, Department of Medicine and Surgery, Parma University Hospital, Parma, Italy.

Paolo Del Rio (P)

General Surgery Unit, Department of Medicine and Surgery, Parma University Hospital, Parma, Italy.

Classifications MeSH